147 related articles for article (PubMed ID: 18977148)
21. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.
Liu LJ; He B; Miles JA; Wang W; Mao Z; Che WI; Lu JJ; Chen XP; Wilson AJ; Ma DL; Leung CH
Oncotarget; 2016 Mar; 7(12):13965-75. PubMed ID: 26883110
[TBL] [Abstract][Full Text] [Related]
23. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
[TBL] [Abstract][Full Text] [Related]
24. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.
Saxena A; Rorie CJ; Dimitrova D; Daniely Y; Borowiec JA
Oncogene; 2006 Nov; 25(55):7274-88. PubMed ID: 16751805
[TBL] [Abstract][Full Text] [Related]
25. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.
Plante JP; Burnley T; Malkova B; Webb ME; Warriner SL; Edwards TA; Wilson AJ
Chem Commun (Camb); 2009 Sep; (34):5091-3. PubMed ID: 20448956
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
27. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress.
Saito A; Hayashi T; Okuno S; Nishi T; Chan PH
J Cereb Blood Flow Metab; 2005 Feb; 25(2):267-80. PubMed ID: 15678128
[TBL] [Abstract][Full Text] [Related]
28. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
29. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
Linares LK; Scheffner M
FEBS Lett; 2003 Nov; 554(1-2):73-6. PubMed ID: 14596917
[TBL] [Abstract][Full Text] [Related]
30. Sagitol D, a New Thiazole Containing Pyridoacridine Alkaloid from a Vietnamese Ascidian.
Utkina NK
Nat Prod Commun; 2015 Sep; 10(9):1547-8. PubMed ID: 26594755
[TBL] [Abstract][Full Text] [Related]
31. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.
Obata M; Kominami R; Mishima Y
Cell Signal; 2012 May; 24(5):1047-52. PubMed ID: 22245141
[TBL] [Abstract][Full Text] [Related]
32. Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
Mazars A; Fåhraeus R
Biotechnol J; 2010 Apr; 5(4):377-84. PubMed ID: 20235143
[TBL] [Abstract][Full Text] [Related]
33. Lissoclibadin 1, a Polysulfur Aromatic Alkaloid from the Indonesian Ascidian Lissoclinum cf. badium, Induces Caspase-Dependent Apoptosis in Human Colon Cancer Cells and Suppresses Tumor Growth in Nude Mice.
Tatsuta T; Hosono M; Rotinsulu H; Wewengkang DS; Sumilat DA; Namikoshi M; Yamazaki H
J Nat Prod; 2017 Feb; 80(2):499-502. PubMed ID: 28181805
[TBL] [Abstract][Full Text] [Related]
34. p53 ubiquitination: Mdm2 and beyond.
Brooks CL; Gu W
Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
[TBL] [Abstract][Full Text] [Related]
35. Petrosamine B, an inhibitor of the Helicobacter pylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge Oceanapia sp.
Carroll AR; Ngo A; Quinn RJ; Redburn J; Hooper JN
J Nat Prod; 2005 May; 68(5):804-6. PubMed ID: 15921437
[TBL] [Abstract][Full Text] [Related]
36. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
[TBL] [Abstract][Full Text] [Related]
37. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
38. Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Pan W; Lahue BR; Ma Y; Nair LG; Shipps GW; Wang Y; Doll R; Bogen SL
Bioorg Med Chem Lett; 2014 Apr; 24(8):1983-6. PubMed ID: 24656661
[TBL] [Abstract][Full Text] [Related]
39. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
40. Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.
Marugan JJ; Leonard K; Raboisson P; Gushue JM; Calvo R; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Schubert C; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3115-20. PubMed ID: 16630722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
